SCYNEXIS INC
SCYXDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How SCYX's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SCY-078 | Phase 3 | Mycoses | - | - |
Ibrexafungerp | Phase 3 | Candida Vulvovaginitis | - | - |
SCY-635 | Phase 2 | Hepatitis C Infection | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in SCYNEXIS INC's drug pipeline?→
CatalystAlert tracks 3 drug candidates in SCYNEXIS INC's (SCYX) pipeline across Phase 3, Phase 2. Its lead program is SCY-078 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is SCYNEXIS INC's next FDA catalyst?→
SCYNEXIS INC's (SCYX) next tracked catalyst is a Phase 1 expected December 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SCYX biotech catalysts?→
Add SCYX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SCYNEXIS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.